Peer2Peer: The Podcast

Rayner

The best conversations about ophthalmology happen when leading surgeons sit down with their peers and explore topics big and small. Each episode brings together rotating hosts and their invited guests resulting in a mix of invaluable insights and unscripted moments you won’t want to miss. Published by Rayner.

  1. 09/30/2025

    Why OMIDRIA Matters: Enhancing Outcomes and Reducing Burden

    Dr Paul Singh and Dr Kendall Donaldson come together at the AECOS 2025 to explore the evolving role of OMIDRIA in cataract surgery. As the only FDA-approved intracameral NSAID, OMIDRIA continues to deliver meaningful clinical benefit - reducing inflammation, preventing complications, and improving patient outcomes - while easing or removing the burden of post-op drop regimens. Listeners will hear real-world insights from the Bascom study and clinical practice, including how OMIDRIA-based dropless protocols can streamline workflow, enhance staff efficiency, improve patient satisfaction, and reduce costs. Importantly, OMIDRIA now maintains separate payment status in both Ambulatory Surgery Centers (ASCs) and Hospital Outpatient Departments (HOPDs) for 100% of fee-for-service Medicare patients.* *OMIDRIA qualifies for separate payment across both ASC and HOPD settings as it fulfils the requirements established in the non-opioid as a surgical supply provision by CMS.    Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo, are proprietary marks of Rayner. © 2025 Rayner Group, all rights reserved. OMIDRIA videos and podcasts are for the attention of US HCPs only. Please rely on your clinical judgment when considering treatment approaches. A dropless approach with OMIDRIA may not suit all patients. Rayner does not recommend specific product combinations. As of August 2025, OMIDRIA is approved in the US and UK. Speakers may be paid Rayner consultants. US-OM-2500051 07/25

    25 min
  2. 06/11/2025

    Sulcoflex Inventor & Experts: “Refractive Surprises Happen to Us All”

    Dr Ben LaHood is joined by Professor Michael Amon - the inventor of the Sulcoflex supplementary IOL - and refractive specialist, Dr Michael Rossiter Thornton to explore the role of the Sulcoflex lens in managing unexpected refractive outcomes. The discussion highlights real-world surgical experiences, strategies for addressing refractive surprises, and how the Sulcoflex lens offers a valuable secondary solution for enhancing visual results post-cataract or refractive lens surgery. This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries. © 2025 Rayner Group, all rights reserved. Rayner and Sulcoflex are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

    25 min

About

The best conversations about ophthalmology happen when leading surgeons sit down with their peers and explore topics big and small. Each episode brings together rotating hosts and their invited guests resulting in a mix of invaluable insights and unscripted moments you won’t want to miss. Published by Rayner.

You Might Also Like